| Patient | Sugar Ray Robinson |
|---|---|
| Date of birth | 1963-05-03 |
| Identifiers | MRN HR-BX003-SYN; SSN (made up) 000-03-9318 |
| Document date | 2026-08-18 |
| Author | Langston Pryce-Okonjo, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Six-week review: amyloid PET result and the diagnosis. [S]
Sugar Ray Robinson returns six weeks after intake with his care partner, whom he asked to be present. The amyloid PET two weeks ago was positive. He was asked first how much he wanted to know and said he wanted it straight. The diagnosis of Alzheimer's disease at the stage of mild dementia was explained with the PET, MRI and test results, in plain words and in writing. He was quiet, then asked whether boxing had caused it; that question was answered honestly. His home glucose readings ran 95 to 150 mg/dL, with one reading of 68 mg/dL before lunch on glipizide. He has not driven. His care partner finds the evenings and the repeated questions tiring. [S]
| Element | Detail |
|---|---|
| Amyloid PET | Positive, widespread cortical uptake |
| Diagnosis | Mild dementia due to Alzheimer's disease, early onset |
| Home glucose | 95 to 150 mg/dL; one reading of 68 mg/dL on glipizide |
| ECG | Sinus rhythm 70, normal intervals |
| Care partner | Zarit Burden Interview 18 (mild), narrative |
| System | Result | Finding |
|---|---|---|
| Neurological | Positive | Memory loss unchanged; no falls |
| Psychiatric | Negative | Sad at the news but not depressed; no thoughts of self-harm |
| Endocrine | Positive | One low glucose reading before lunch, with sweating |
3 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Metformin 1,000 mg oral tablet, one tablet twice daily with meals | One tablet twice daily with meals | Oral route | 2024-03-01 | active | S |
| Glipizide 5 mg oral tablet, one tablet before breakfast | One tablet before breakfast | Oral route | 2025-01-15 to 2026-08-18 | completed | S |
| Lisinopril 20 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2023-06-01 | active | S |
| Atorvastatin 20 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2024-03-01 | active | S |
| Diphenhydramine 25 mg oral capsule, one at bedtime for sleep, bought over the counter | One capsule at bedtime | Oral route | 2025-10-01 to 2026-07-07 | stopped | S |
| Donepezil 5 mg oral tablet, one tablet at bedtime | One tablet at bedtime | Oral route | 2026-08-18 to 2026-09-22 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-08-18 | Body height | 180 | cm | S |
| 2026-08-18 | Body weight | 76.6 | kg | S |
| 2026-08-18 | Body mass index (BMI) [Ratio] | 23.6 | kg/m2 | S |
| 2026-08-18 | Systolic blood pressure | 126 | mm[Hg] | S |
| 2026-08-18 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-08-18 | Heart rate | 70 | /min | S |
| 2026-08-18 | Respiratory rate | 14 | /min | S |
| 2026-08-18 | Body temperature | 36.6 | Cel | S |
| 2026-08-18 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
Vital signs recorded on 2026-08-18; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 126/78; pulse 70; weight 76.6 kg |
| Mental status | Attentive during the disclosure; asks good questions; mood sad but reactive |
| Gait | Steady; Timed Up and Go 9 seconds |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Memory loss over about two years, worse in the past six months, with repeated questions, missed appointments and bills, and getting lost twice while driving in familiar streets, reported by him and his care partner; cause to be found | resolved | confirmed | R41.3 | S — Synthetic presenting problem anchored to his documented Alzheimer's disease; resolved into the diagnosis at the third visit. Not a claim about his real symptoms at that age. |
| Alzheimer's disease with early onset, confirmed by a positive amyloid PET, with an amnestic presentation; traumatic encephalopathy syndrome, a research diagnosis, considered | active | confirmed | G30.0 | S — Synthetic modern diagnosis by current criteria at the third visit; not a retrospective diagnosis of the historical person beyond the documented Alzheimer's disease. |
| Mild dementia due to Alzheimer's disease (CDR 1, MMSE 22, MoCA 18), without behavioral or psychological symptoms | active | confirmed | F02.A0 | S — Synthetic stage at diagnosis. |
| Type 2 diabetes for about ten years on metformin and glipizide; hemoglobin A1c 6.4%, below his goal, with hypoglycemia risk from the sulfonylurea | active | confirmed | E11.9 | S — Synthetic modern diabetes anchored to his documented diabetes. |
| Hypertension, controlled on lisinopril | active | confirmed | I10 | S — Synthetic modern hypertension anchored to the single press report. |
| Bilateral sensorineural hearing loss, mild to moderate, high frequencies, on audiometry | active | confirmed | H90.3 | S — Synthetic finding checked as a modifiable contributor to cognitive difficulty. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | Cognitive testing (MoCA, MMSE) | At diagnosis, then yearly, or sooner with change | Up to date | MoCA 18 and MMSE 22 at diagnosis; next in a year |
| Survey | Dementia staging (CDR) and function (ADL and IADL) | At diagnosis, then yearly | Up to date | CDR 1 two weeks ago |
| Imaging | Amyloid biomarker confirmation (PET or CSF) | Once, when it will change diagnosis or treatment | Completed today | Amyloid PET positive (about 90 Centiloids), reviewed with him today |
| Medication safety | Anti-amyloid antibody eligibility (lecanemab, donanemab), APOE genotyping and ARIA MRI schedule | At diagnosis of MCI or mild dementia due to Alzheimer's disease | Not indicated | Not a candidate because of six microbleeds; explained to him today |
| Medication safety | Medicine review for anticholinergic and sedating drugs (Beers) | Every visit | Completed today | No anticholinergic or sedating drugs; glipizide stopped for hypoglycemia risk |
| Survey | Behavioral and psychological symptoms (NPI-Q items) | Every visit | Completed today | None; sad at the news without depression |
| Medication safety | Cholinesterase inhibitor: benefit, nausea, diarrhea, dreams, pulse | Each follow-up and each dose change | Completed today | Donepezil 5 mg started after a normal ECG (pulse 70) |
| Self-management | Driving, firearm and home safety | At diagnosis and each follow-up | Completed today | Agreed to stop driving; handgun to be removed from the home; stove shut-off advised |
| Self-management | Care partner support and burden (Zarit, narrative) | At diagnosis, then at least yearly | Completed today | Zarit 18 (mild burden); helpline, caregiver class and adult day program arranged; GUIDE explained for when he has Medicare |
| Self-management | Advance care planning | At diagnosis; revisit yearly and at changes | Due | Booked at the preventive visit in three weeks, while he can take part fully |
| Laboratory | Hemoglobin A1c, goal under 8.0% for an older adult with cognitive impairment, and hypoglycemia review | Every three months after a therapy change; every six months when stable | Up to date | 6.4% at intake; one low reading; glipizide stopped; A1c due in about three months |
| Examination | Blood pressure, goal under 130/80 mmHg | Every visit | Completed today | 126/78 mmHg |
| Laboratory | Potassium and creatinine on lisinopril and metformin | Yearly, and after acute illness or dehydration | Up to date | Normal at intake |
| Examination | Dilated diabetic eye examination | Every one to two years without retinopathy | Referred | Still pending; he now depends on others for transport |
| Self-management | Exercise and social activity | Every visit | Completed today | Walks daily; the foundation gym twice a week |
Goal progress:
Guideline basis: Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for specialty care (2024); CMID: Clinical Monitoring Intelligence Database, Alzheimer's disease, diabetes type 2 and hypertension monographs (2026); Lecanemab: Appropriate Use Recommendations (2023); Donanemab: Appropriate use recommendations (2025); National Institute of Neurological Disorders and Stroke Consensus Diagnostic Criteria for Traumatic Encephalopathy Syndrome (2021); 13. Older Adults: Standards of Care in Diabetes-2026 (2026); Practice Parameter update: Evaluation and management of driving risk in dementia (2010); Guiding an Improved Dementia Experience (GUIDE) Model (2024)
Follow-up: Preventive visit with advance care planning in three weeks. Hearing aid fitting in two weeks. Eleven-week review with hemoglobin A1c. Call for low glucose readings, falls, or nausea on donepezil. Next scheduled visit 2026-09-08: periodic adult preventive visit. [S]